Novo Nordisk ADR [NVO] stock is trading at $57.2, up 2.84%. An important factor to consider is whether the stock is rising or falling in short-term value. The NVO shares have gain 5.34% over the last week, with a monthly amount glided 9.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on September 16, 2025, when Rothschild & Co Redburn upgraded its rating to a Buy. Previously, Bernstein upgraded its rating to Outperform on September 09, 2025. On August 13, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $54 on the stock. UBS downgraded its rating to a Neutral. HSBC Securities downgraded its rating to a Hold but $57 remained the price target by the analyst firm on July 31, 2025. Barclays downgraded its rating to Equal Weight for this stock on July 30, 2025. In a note dated April 17, 2025, BMO Capital Markets downgraded a Market Perform rating on this stock but restated the target price of $64.
Novo Nordisk ADR [NVO] stock has fluctuated between $45.05 and $138.22 over the past year. Currently, Wall Street analysts expect the stock to reach $52.5 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $57.2 at the most recent close of the market. An investor can expect a potential drop of -8.22% based on the average NVO price forecast.
Analyzing the NVO fundamentals
Novo Nordisk ADR [NYSE:NVO] reported sales of 45.45B for the trailing twelve months, which represents a growth of 18.96%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.45%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.23, Equity is 0.78 and Total Capital is 0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Novo Nordisk ADR’s Current Ratio is 0.78. On the other hand, the Quick Ratio is 0.56, and the Cash Ratio is 0.09. Considering the valuation of this stock, the price to sales ratio is 4.24, the price to book ratio is 9.61 and price to earnings (TTM) ratio is 15.76.
Transactions by insiders
Recent insider trading involved Novo Nordisk A/S, 10% Owner, that happened on May 30 ’25 when 0.92 million shares were purchased.
